I-Cybin Therapeutics, inkampani yabucala yonyango lwebhayoloji kwinjongo yokufumanisa nokuphuhlisa iiprothokholi zonyango ezincediswa yi-psilocybin, inelayisensi ye-PEX010 (25 mg) esuka kwi-Filament ukuze isetyenziswe kulingo. Ulingo kulindeleke ukuba luqale kwi-Q3'22 kwaye luya kubandakanya abantu abaneengxaki ezinkulu zokudakumba abafumana unyango olukhethiweyo lwe-serotonin reuptake inhibitor (SSRI), esetyenziswa ngokuqhelekileyo ukunyanga ukudakumba, kunye nabo bangenayo i-SSRI-naive.
“Ukwamkelwa kweHealth Canada kububungqina bokuba unyanisekile kolu lingo kwakunye nokukwazi kukaFilament ukuvelisa kunye nelayisenisi abagqatswa bamayeza ezityalo akwinqanaba loxubo-mayeza,” latsho iGosa eliyiNtloko yeSigqeba uFilament, uBenjamin Lightburn. "Isiphumo sonyango lwe-psilocybin kwizigulana ezithatha amayeza e-SSRI athomalalisa uxinzelelo luphando olubaluleke kakhulu kwaye siyakuvuyela ukuthatha inxaxheba kolu phando lubalulekileyo."
"Uninzi lwabantu baseCanada abalwa nokudakumba bafumana unyango lwe-SSRI, kwaye ukuza kuthi ga ngoku, oku kuthetha ukukhutshelwa ngaphandle kulingo lwezonyango lwengqondo encediswa yi-psychedelic (PAP)," utshilo uJosh Taylor, uMseki weCybin Therapeutics. "Ukuba kunokubonakaliswa ukuba i-PAP inokunikezelwa ngokukhuselekileyo nangempumelelo kwizigulane ezikwii-SSRIs, abaninzi baya kuxhamla. Sivakalelwa kukuba eli lithuba elibalaseleyo lokubonisa i-Health Canada ukuba iCybin Therapeutics inokuphucula iziphumo zesigulana kunye neqela lethu kwaye iphuhlise imigaqo.
I-Filament iphinde ilayisenisi i-PEX010 (25 mg) kwi-CT kwizilingo ezongezelelweyo zesigaba se-2, ekulindeleke ukuba ziqale kwikota yesine ye-2022. Zombini izilingo ziya kukhokelwa nguDkt Reg Peters noDave Phillips.
